Fed. Circ. Sides With Otsuka In Abilify Patent Validity Debate
The Federal Circuit on Monday affirmed a lower court's ruling that the patent for Otsuka Pharmaceutical Co. Ltd.'s schizophrenia drug Abilify was valid and not obvious, rejecting challenges by companies seeking...To view the full article, register now.
Already a subscriber? Click here to view full article